Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy.
about
Predictors of growth and body composition in HIV-infected children beginning or changing antiretroviral therapyLongitudinal changes in regional fat content in HIV-infected children and adolescents.Lipodystrophy syndrome among HIV infected children on highly active antiretroviral therapy in northern IndiaNutritional status and lipid profile of HIV-positive children and adolescents using antiretroviral therapy.Body composition in childhood: effects of normal growth and disease.Body fat distribution in perinatally HIV-infected and HIV-exposed but uninfected children in the era of highly active antiretroviral therapy: outcomes from the Pediatric HIV/AIDS Cohort Study.Gastrointestinal and nutritional complications of human immunodeficiency virus infectionChanges in macronutrient intake among HIV-infected children between 1995 and 2004.Cardiac effects in perinatally HIV-infected and HIV-exposed but uninfected children and adolescents: a view from the United States of America.Metabolic complications and treatment of perinatally HIV-infected children and adolescents.Morphologic and metabolic abnormalities in vertically HIV-infected children and youth.Growth and puberty in children with HIV infection.Metabolic complications associated with antiretroviral therapy in HIV-infected and HIV-exposed uninfected paediatric patients.Patterns of Growth, Body Composition, and Lipid Profiles in a South African Cohort of Human Immunodeficiency Virus-Infected and Uninfected Children: A Cross-Sectional Study.Body composition in prepubertal, HIV-infected children: a comparison of bioelectrical impedance analysis and dual-energy X-ray absorptiometry.PENTA guidelines for the use of antiretroviral therapy, 2004.Lipodystrophy in HIV-infected pediatric patients receiving protease inhibitors.Regional body fat distribution in HIV-infected patients with lipodystrophy.Fat distribution is altered in HIV-infected men without clinical evidence of the HIV lipodystrophy syndrome.
P2860
Q28741211-C2ABC269-E168-47CF-AC47-1A099BC15AD2Q33693051-EDCE46A4-7037-4984-9FD4-9C5E30DC1E19Q34335535-8192E159-1ED1-4CB2-96E4-9FC6E34131BAQ35087195-F40BF151-062D-4861-BC68-88012835702EQ35542219-E44C2E43-F19D-4DB6-9C07-95AB8311AA61Q35656425-24B1D885-6025-4784-9BB7-E26604AC091AQ36233095-0DF24788-4A46-4925-94B8-5C0FCEF35AAEQ36924360-F04182A9-5AEF-4B68-B16E-4224784E614DQ36941650-C01F0BBC-FF97-493F-B552-32BD356582F2Q36952291-EDB4B8FC-E6C3-465A-B5AB-E6576EC962B4Q37187093-E0BC5109-144A-4022-9B39-B0D18D285627Q37428510-47FD5E34-92E1-4BBE-80B9-8A1306AE258AQ37676229-C935A168-B2DF-45B3-8F73-B356989791B5Q38798094-F6449945-4C80-4044-A531-21B76E085FF6Q42273064-6A84D80A-190E-42CC-B230-1B574A759C4FQ44263320-97103292-77CE-4F61-9659-6897429EB08DQ44551426-CF5347A8-F993-4CCD-8337-63EF8801C758Q46605586-E00DF43E-ABBA-4749-9C57-F725AE7F3000Q53647308-DFC7829C-05E4-4FBB-A53B-0799F7D60273
P2860
Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Highly active antiretroviral-t ...... n in absence of lipodystrophy.
@en
Highly active antiretroviral-t ...... n in absence of lipodystrophy.
@nl
type
label
Highly active antiretroviral-t ...... n in absence of lipodystrophy.
@en
Highly active antiretroviral-t ...... n in absence of lipodystrophy.
@nl
prefLabel
Highly active antiretroviral-t ...... n in absence of lipodystrophy.
@en
Highly active antiretroviral-t ...... n in absence of lipodystrophy.
@nl
P2093
P1433
P1476
Highly active antiretroviral-t ...... n in absence of lipodystrophy.
@en
P2093
Brambilla P
Bricalli D
Chiumello G
Renzetti F
di Natale B
P304
P356
10.1097/00002030-200112070-00009
P407
P577
2001-12-01T00:00:00Z